ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,720Medicare Part D Prescriptions Filled, Including Refills

Rank: 194 out of 2456

$2,079 Total Retail Price of All Prescriptions

Rank: 2448 out of 2456

226 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
100% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 226 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

13% of this provider’s 226 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 8,913 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$0 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

43 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
FUROSEMIDE 333 327 1 8
DONEPEZIL HCL 297 297 2 23
LISINOPRIL 291 266 3 1
SIMVASTATIN 283 270 4 2
CITALOPRAM HBR 230 222 5 14
LEVOTHYROXINE SODIUM 227 222 6 4
MIRTAZAPINE 209 209 7 29
SERTRALINE HCL 201 168 8 21
CALCIUM 600 + VIT D 197 166 9 270
OMEPRAZOLE 165 156 10 3
ATENOLOL 145 139 11 6
DAILY MULTIPLE VITAMIN 145 125 10 11 317
AMLODIPINE BESYLATE 143 143 13 5
GABAPENTIN 139 112 14 16
CALCIUM WITH VITAMIN D 124 124 15 331
METOPROLOL TARTRATE 115 103 16 10
MULTIVITAMINS 110 86 17 398
NAMENDA 109 109 18 42
METFORMIN HCL 105 86 19 11
POTASSIUM CHLORIDE 105 103 19 33
WARFARIN SODIUM 105 105 19 9
TRAZODONE HCL 95 74 22 17
CERTAVITE SENIOR-ANTIOXIDANT 90 90 23 407
DAILY VITE 89 77 24 358
ASPIRIN EC 88 82 25 266
FERROUS SULFATE 87 84 26 412
DOK 80 80 27 416
PRILOSEC OTC 78 75 28 417
HYDROCODONE-ACETAMINOPHEN 78 64 S3 28 20
PAROXETINE HCL 66 60 30 56
RANITIDINE HCL 64 42 31 31
LORAZEPAM 63 45 32 67
SENNA 61 54 33 448
DIOVAN 61 61 33 26
METOPROLOL SUCCINATE 61 51 33 13
TAMSULOSIN HCL 60 60 36 32
ALENDRONATE SODIUM 59 51 37 19
PREDNISONE 58 57 38 39
CYMBALTA 58 58 38 65
ALLOPURINOL 57 57 40 27
ASPIRIN 55 54 41 368
TERAZOSIN HCL 54 54 42 76
RISPERIDONE 50 45 43 50
ADVAIR DISKUS 50 38 43 36
STOOL SOFTENER 50 50 43 403
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 4, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.